CART-ddBCMA is a BCMA directed CAR T cell therapy in development for multiple myeloma.

SparkCures ID 363
Developed By Arcellx, Inc.
Generic Name CART-ddBCMA
Treatment Classifications
Treatment Targets

Clinical Trials

All Clinical Trials

View all active clinical trials around the US.

Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

Smoldering Myeloma
Monoclonal Gammopathy of Undetermined Significance (MGUS)